Skip Navigation


NDT Advance Access originally published online on February 6, 2007
Nephrology Dialysis Transplantation 2007 22(4):1062-1069; doi:10.1093/ndt/gfl810
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/4/1062    most recent
gfl810v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koepke, M.-L.
Right arrow Articles by Gross, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koepke, M.-L.
Right arrow Articles by Gross, O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome

Marie-Louise Koepke1, Manfred Weber1, Eckhard Schulze-Lohoff1, Bogdan Beirowski2, Stephan Segerer3 and Oliver Gross1,4

1Department of Internal Medicine I, Cologne General Hospital, Merheim Medical Center, 2Department of Anatomy I, University of Cologne, 3Medizinische Poliklinik-Innenstadt, University of Munich, Munich and 4Department of Nephrology & Rheumatology, University of Göttingen, Göttingen, Germany

Correspondence and offprint requests to: PD Dr Oliver Gross, MD, FASN, Department of Nephrology & Rheumatology, University of Göttingen, Robert-Koch-Str. 40, D- 37075 Göttingen, Germany. Email: gross.oliver{at}med.uni-goettingen.de



  Abstract

Background. Alport syndrome is caused by mutations in genes encoding for the {alpha}3, {alpha}4 or {alpha}5 chain of type IV collagen leading to excessive production of fibrotic tissue and end-stage renal failure. HMG-CoA-reductase-inhibitors exhibit pleiotropic effects by which they modulate the production of connective tissue. The aim of this study was to examine the anti-fibrotic effect of the HMG-CoA-reductase-inhibitor, cerivastatin, in COL4A3 knockout mice, an animal model of Alport syndrome with progressive renal fibrosis.

Methods. Forty homozygous COL4A3 knockout mice received cerivastatin, starting 28 or 49 days after birth. Mice were sacrificed at day 52 or 66 after birth. Immunohistochemistry against laminin and fibronectin was performed. Inflammatory cell infiltration was determined by F4/80- and CD3-staining. Myofibroblasts were identified by an {alpha}-smooth muscle actin staining. Expression of the profibrotic cytokines, TGF-ß1 and CTGF, were determined by immunoblot.

Results. The lifespan of treated COL4A3 knockout mice was increased by 28% compared with untreated animals (71 ± 6 vs 91 ± 9 days, P < 0.01). Early cerivastatin treatment reduced cholesterol levels (113 ± 13 vs 141 ± 19 mmol/l in untreated animals, P < 0.05) and serum urea (164 vs 235 mmol/l, day 66, P < 0.05). Treatment also decreased proteinuria (5.5 vs 12 g/l at day 66, P < 0.05). Deposition of laminin and fibronectin, expression of TGF-ß and CTGF was reduced. Infiltration of T-cells and macrophages as well as myofibroblasts appeared to be reduced in kidneys from cerivastatin-treated mice.

Conclusion. Cerivastatin prolongs the lifespan of COL4A3 knockout mice, reduces proteinuria and delays uraemia. These effects are associated with decreased renal fibrosis and a reduction of inflammatory cell infiltration.

Keywords: alport syndrome; extracellular matrix; renal fibrosis; statins; type IV collagen

Received for publication: 7. 8.06
Accepted in revised form: 12.12.06


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

In this issue ...

NDT 2007 22: i. [Extract] [FREE Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.